Research teams need to obtain faster and more timely answers to their business questions.
Because of evolving market dynamics, it is increasingly essential that pharmas get their forecasting right, whether for a broad therapy area or a sub-population of patients. However, most research methods have limitations that can result in inaccurate forecasts — with costly repercussions.
Our data scientists and epidemiologists combine epidemiology with real world data, helping pharma teams gain a deep understanding of a disease population for more accurate biopharma market sizing & forecasting analytics and greater confidence in planning commercial investments.
“Working with the Clarivate team showed me the power of linking claims with EHR for sizing and understanding patient populations and the impact on your business decisions – that was a lightbulb moment for me. I really value that partnership of being able to call up my Clarivate specialist to brainstorm how to use this integrated data to tackle our most challenging questions.”
Clarivate combines epidemiology and real world data so research teams can:
Benchmark your forecasts with biopharma market data on the total potential and addressable market
Validate your investments using bottom-up forecasting
Identify growth opportunities and understand how populations will change over time
Track disease stages, sub-populations and treatment flow
Estimate drug-treated populations with insights from therapeutic experts and primary biopharma market research
We partner with brand teams to answer tough business questions, laying the groundwork for precise forecasting and strategic implementation:
Segment by therapy area
Segment by sub-population
By fusing multiple data sources, true market opportunity is revealed, sales force teams are optimized, and commercial effectiveness is enabled:
Electronic health records
Health plan formulary & lives
Healthcare provider affiliation directory